With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

By Kami McDonald, Student Pharmacist and Karen L. Kier, Pharmacist ONU Healthwise Pharmacy ...

Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval decision in 2023. In November 2024, the FDA also found quality control lapses ...

Feeding rats edible microbeads designed to absorb fat helps them lose weight. One day the beads could be used in human foods and drinks to prevent or treat obesity in people.

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

Women using Ozempic and similar drugs are reporting changes in the vulva area, termed 'Ozempic vulva,' including sagging, ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.